eXoZymes (EXOZ) Q4 2025 earnings summary

Executive summary

• Strategy in 2025 shifted to prioritize asset ownership and high-value product programs, notably NCT and cannabinoids, over broad partnerships, aiming for greater value capture and commercial maturity.

• Cell-free biomanufacturing platform advanced from concept to pilot and commercial scale, demonstrating superior speed, purity, scalability, and process control, enabling production of rare molecules like NCT.

• NCT program achieved kilo-scale pilot production, successful tech transfer to Cayman Chemical, and is positioned for nutraceutical and pharmaceutical market entry.

• Multi-channel commercialization strategy for NCTx targets both nutraceutical and pharmaceutical markets, leveraging partnerships and contract manufacturing for capital efficiency.

• Pipeline includes cannabinoids, santalene, and other novel molecules, with AI-assisted enzyme engineering accelerating innovation and asset identification.

Financial highlights

• Cash and cash equivalents at year-end 2025 were $3.04 million, sufficient to fund operations into mid-Q2 2026.

• Total operating expenses for 2025 were $9.72 million, up from $5.93 million in 2024, mainly due to increased R&D and personnel investments.

• Net loss for 2025 was $9.16 million, compared to $5.86 million in the prior year.

Outlook and guidance

• Preparing for a new financing round, with S-3 filed in January 2026 and investor roadshows underway; capital efficiency and lean operations remain a priority.

• Key upcoming milestones include human use studies for NCT, completion of tech transfer packages, and further progress in the cannabinoid program.

• Commercial launch of NCT targeted for 2027, with ongoing process optimization and regulatory submissions in 2026.